After the Chip: U.S. Biotech Sanctions Begin, China’s Innovative Drug Breakthrough Battle Commences
Recently, the U.S. restrictions on the Chinese biotechnology sector have shifted from “expectation” to “actual action”. On September 12, 2025, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) placed 23 Chinese entities on the “Entity List”, including three biotechnology companies: Beijing Tianyi Huiyuan Biotechnology Co., Ltd., Beijing Qinke Biotechnology Co., Ltd., and … Read more